The human microbiome is associated with human health and disease. Exogenous
compounds, including pharmaceutical products, are also known to be affected by the …

Background Following solid organ transplantation, tacrolimus (TAC) is an essential drug in
the immunosuppressive strategy. Its use constitutes a challenge due to its narrow …

Our understanding of the scope and clinical relevance of gut microbiota metabolism of drugs
is limited to relatively few biotransformations targeting a subset of therapeutics. Translating …

The gut microbiome harbors trillions of organisms that contribute to human health and
disease. These bacteria can also affect the properties of medical drugs used to treat these …

The microbiome not only represents a vital modifier of health and disease, but is a clinically
important drug target. Therefore, study of the impact of the human microbiome on drug …

The human microbiota directly and indirectly impacts drug pharmacokinetics and
pharmacodynamics, thus affecting treatment outcome and subsequently human health. The …

Introduction: Pharmacomicrobiomics and toxicomicrobiomics study how variations within the
human microbiome (the combination of human-associated microbial communities and their …

Individual variability in drug response (IVDR) can be a major cause of adverse drug
reactions (ADRs) and prolonged therapy, resulting in a substantial health and economic …

The microbiome, a collection of microorganisms, their genomes, and the surrounding
environmental conditions, is akin to a human organ, and knowledge is emerging on its role …

Our bodies each possess a unique and dynamic collection of microbes and viruses,
collectively the 'microbiome', with distinct metabolic capacities from our human cells …